The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin ' s Lymphoma (NHL)

Conditions: Non-hodgkin Lymphoma,B Cell Interventions: Biological: CART-19 and 20 cells; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: Henan Cancer Hospital Recruiting

https://clinicaltrials.gov/study/NCT06160362

Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials